cAMP can regulate the activity of MEG3 through a cAMP response element (CRE) in the proximal promoter region of MEG3, and then mediate cis-platinum resistance in lung cancer patients through regulating interactions between MEG3 and its downstream effectors 90. The gene discussed is MEG3; the disease is lung carcinoma.